Contineum Therapeutics Inc
CTNM5.750USD
-0.210-3.52%
交易中 （美東）報價延遲15分鐘
148.76M總市值
虧損本益比TTM
關於 Contineum Therapeutics Inc 公司
Continum Therapeutics, Inc. 是一家臨牀階段的生物製藥公司。該公司專注於發現和開發新型口服小分子療法，這些療法針對與特定臨牀損傷相關的生物途徑，用於治療具有高度未滿足需求的神經科學、炎症和免疫學 (NI&I) 適應症。其產品線包括 PIPE-791、CTX-343 和 PIPE-307。其主要資產 PIPE-791 是一種新型腦滲透性溶血磷脂酸 1 受體 (LPA1R) 小分子抑制劑，正在開發用於特發性肺纖維化 (IPF) 和進行性多發性硬化症 (Progressive MS)。該公司正在開發 CTX-343，一種外周受限的 LPA1R 拮抗劑，以進一步擴大涉及 LPA1R 拮抗作用的臨牀適應症。其第二種候選藥物 PIPE-307 是一種新型小分子選擇性 M1R 抑制劑，目前正在臨牀開發中，用於治療抑鬱症和復發緩解型 MS (RRMS)。
公司簡介
公司代碼CTNM
公司名稱Contineum Therapeutics Inc
上市日期Apr 05, 2024
CEOMr. Carmine Stengone
員工數量41
證券類型Ordinary Share
年結日Apr 05
公司地址3565 General Atomics Court, Suite 200
城市SAN DIEGO
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編92121
電話18583335280
網址https://www.contineum-tx.com/
公司代碼CTNM
上市日期Apr 05, 2024
CEOMr. Carmine Stengone
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Timothy Watkins, M.D.
Dr. Timothy Watkins, M.D.
Chief Medical Officer and Head of Development
Chief Medical Officer and Head of Development
--
--
Dr. Diego Miralles, M.D.
Dr. Diego Miralles, M.D.
Director
Director
--
--
Ms. Sarah Boyce
Ms. Sarah Boyce
Independent Director
Independent Director
--
--
Ms. Lori M. Lyons-Williams
Ms. Lori M. Lyons-Williams
Independent Director
Independent Director
--
--
Mr. Evert B. (Eef) Schimmelpennink
Mr. Evert B. (Eef) Schimmelpennink
Independent Director
Independent Director
--
--
Ms. Kristina Haeckl
Ms. Kristina Haeckl
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
--
--
Mr. Carmine Stengone
Mr. Carmine Stengone
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Mr. Troy A. Ignelzi
Mr. Troy A. Ignelzi
Independent Director
Independent Director
--
--
Mr. John Healy
Mr. John Healy
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
Dr. Daniel S. Lorrain, Ph.D.
Dr. Daniel S. Lorrain, Ph.D.
Chief Science Officer
Chief Science Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Timothy Watkins, M.D.
Dr. Timothy Watkins, M.D.
Chief Medical Officer and Head of Development
Chief Medical Officer and Head of Development
--
--
Dr. Diego Miralles, M.D.
Dr. Diego Miralles, M.D.
Director
Director
--
--
Ms. Sarah Boyce
Ms. Sarah Boyce
Independent Director
Independent Director
--
--
Ms. Lori M. Lyons-Williams
Ms. Lori M. Lyons-Williams
Independent Director
Independent Director
--
--
Mr. Evert B. (Eef) Schimmelpennink
Mr. Evert B. (Eef) Schimmelpennink
Independent Director
Independent Director
--
--
Ms. Kristina Haeckl
Ms. Kristina Haeckl
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月29日 週二
更新時間: 7月29日 週二
持股股東
股東類型
持股股東
持股股東
佔比
RA Capital Management, LP
11.09%
Johnson & Johnson Innovation-JJDC, Inc.
10.34%
Suvretta Capital Management, LLC
8.99%
Franklin Advisers, Inc.
8.23%
Perceptive Advisors LLC
7.53%
Other
53.83%
持股股東
持股股東
佔比
RA Capital Management, LP
11.09%
Johnson & Johnson Innovation-JJDC, Inc.
10.34%
Suvretta Capital Management, LLC
8.99%
Franklin Advisers, Inc.
8.23%
Perceptive Advisors LLC
7.53%
Other
53.83%
股東類型
持股股東
佔比
Venture Capital
29.30%
Investment Advisor/Hedge Fund
20.96%
Investment Advisor
16.09%
Hedge Fund
15.95%
Private Equity
7.53%
Individual Investor
1.82%
Sovereign Wealth Fund
0.89%
Research Firm
0.25%
Bank and Trust
0.06%
Other
7.16%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
117
15.65M
81.77%
-1.46M
2025Q1
118
15.85M
82.82%
-1.26M
2024Q4
110
17.13M
89.94%
+2.97M
2024Q3
93
14.98M
78.62%
+2.09M
2024Q2
74
14.21M
74.59%
+7.65M
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Johnson & Johnson Innovation-JJDC, Inc.
1.98M
10.34%
--
--
Mar 31, 2025
Suvretta Capital Management, LLC
1.72M
8.99%
--
--
Mar 31, 2025
Franklin Advisers, Inc.
1.58M
8.23%
+130.62K
+9.04%
Mar 31, 2025
Perceptive Advisors LLC
1.44M
7.53%
--
--
Mar 31, 2025
Versant Ventures
918.16K
4.8%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
810.32K
4.23%
+118.44K
+17.12%
Mar 31, 2025
The Vanguard Group, Inc.
803.43K
4.2%
-5.66K
-0.70%
Mar 31, 2025
Sectoral Asset Management Inc.
800.79K
4.18%
--
--
Mar 31, 2025
HHLR Advisors, Ltd.
669.34K
3.5%
--
--
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0.01%
Schwab U.S. Small-Cap ETF
0%
iShares Neuroscience and Healthcare ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
Royce Quant Small-Cap Quality Value ETF
0%
ProShares Hedge Replication ETF
0%
Janus Henderson Small Cap Growth Alpha ETF
0%
Janus Henderson Small/Mid Cap Growth Alpha ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
查看更多
iShares Micro-Cap ETF
佔比0.01%
Schwab U.S. Small-Cap ETF
佔比0%
iShares Neuroscience and Healthcare ETF
佔比0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
佔比0%
Royce Quant Small-Cap Quality Value ETF
佔比0%
ProShares Hedge Replication ETF
佔比0%
Janus Henderson Small Cap Growth Alpha ETF
佔比0%
Janus Henderson Small/Mid Cap Growth Alpha ETF
佔比0%
Global X Russell 2000 ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
